Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Халавен® (эрибулин) стал доступен в России для пациентов с неоперабельной липосаркомой – первый препарат, достоверно увеличивающий общую выживаемость пациентов с редкими агрессивными формами рака
Халавен® (эрибулин) стал доступен в России для пациентов с неоперабельной липосаркомой – первый препарат, достоверно увеличивающий общую выживаемость пациентов с редкими агрессивными формами рака
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Изменение регистрационного удостоверения на препарат Халавен® последовало после проведения международного исследования фазы III, в рамках которого было продемонстрировано увеличение медианы общей выживаемости пациентов с липосаркомой на 7,2 мес
Полный текст
Список литературы
1. Инструкция по медицинскому применению препарата Халавен®: РУ ЛП-001782 от 24.07.2012, с изменениями от 15.06.2016. / Instruktsiia po meditsinskomu primeneniiu preparata KhalavenR: RU LP-001782 ot 24.07.2012, s izmeneniiami ot 15.06.2016. [in Russian]
2. Schöffski P et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016.
3. Chawla S, Schöffski P, Grignani G et al. Subtype-specific Activity in Liposarcoma Patients From a Phase 3, Open-label, Randomized Study of Eribulin Versus Dacarbazine in Patients With Advanced Liposarcoma or Leiomyosarcoma. Poster No.163. Presented at the American Society for Clinical Oncology annual meeting, June 3–7, 2016; Chicago, Illinois.
4. Hudgens S et al. Evaluation of quality of life at progression in patients with soft tissue sarcoma. American Society for Clinical Oncology annual meeting 2016; Abstract #11015.
5. Gelderblom H et al. Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcoma: Health-related quality of life results. Presented at ECC 2015. Abstract #3441
6. Kawano S et al. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. Anticancer Res 2016; 36: 1553–62.
7. Kevin L. Bennewith and Shoukat Dedhar. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 2011; 11: 504.
2. Schöffski P et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016.
3. Chawla S, Schöffski P, Grignani G et al. Subtype-specific Activity in Liposarcoma Patients From a Phase 3, Open-label, Randomized Study of Eribulin Versus Dacarbazine in Patients With Advanced Liposarcoma or Leiomyosarcoma. Poster No.163. Presented at the American Society for Clinical Oncology annual meeting, June 3–7, 2016; Chicago, Illinois.
4. Hudgens S et al. Evaluation of quality of life at progression in patients with soft tissue sarcoma. American Society for Clinical Oncology annual meeting 2016; Abstract #11015.
5. Gelderblom H et al. Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcoma: Health-related quality of life results. Presented at ECC 2015. Abstract #3441
6. Kawano S et al. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. Anticancer Res 2016; 36: 1553–62.
7. Kevin L. Bennewith and Shoukat Dedhar. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 2011; 11: 504.
2. Schöffski P et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016.
3. Chawla S, Schöffski P, Grignani G et al. Subtype-specific Activity in Liposarcoma Patients From a Phase 3, Open-label, Randomized Study of Eribulin Versus Dacarbazine in Patients With Advanced Liposarcoma or Leiomyosarcoma. Poster No.163. Presented at the American Society for Clinical Oncology annual meeting, June 3–7, 2016; Chicago, Illinois.
4. Hudgens S et al. Evaluation of quality of life at progression in patients with soft tissue sarcoma. American Society for Clinical Oncology annual meeting 2016; Abstract #11015.
5. Gelderblom H et al. Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcoma: Health-related quality of life results. Presented at ECC 2015. Abstract #3441
6. Kawano S et al. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. Anticancer Res 2016; 36: 1553–62.
7. Kevin L. Bennewith and Shoukat Dedhar. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 2011; 11: 504.
________________________________________________
2. Schöffski P et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet 2016.
3. Chawla S, Schöffski P, Grignani G et al. Subtype-specific Activity in Liposarcoma Patients From a Phase 3, Open-label, Randomized Study of Eribulin Versus Dacarbazine in Patients With Advanced Liposarcoma or Leiomyosarcoma. Poster No.163. Presented at the American Society for Clinical Oncology annual meeting, June 3–7, 2016; Chicago, Illinois.
4. Hudgens S et al. Evaluation of quality of life at progression in patients with soft tissue sarcoma. American Society for Clinical Oncology annual meeting 2016; Abstract #11015.
5. Gelderblom H et al. Randomized, open-label, multicenter, phase 3 study of eribulin versus dacarbazine in patients with leiomyosarcoma and adipocytic sarcoma: Health-related quality of life results. Presented at ECC 2015. Abstract #3441
6. Kawano S et al. Antimitotic and Non-mitotic Effects of Eribulin Mesilate in Soft Tissue Sarcoma. Anticancer Res 2016; 36: 1553–62.
7. Kevin L. Bennewith and Shoukat Dedhar. Targeting hypoxic tumour cells to overcome metastasis. BMC Cancer 2011; 11: 504.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.